Thrombosis Post-mRNA-based SARS-CoV-2 Vaccination (BNT162b2) - Time to Think Beyond Thrombosis with Thrombocytopenia Syndrome (TTS)

Overview

Journal Thromb Update

Date 2024 Apr 15

PMID 38620755

Authors

Zohaib Yousaf

Fateen Ata

Riyadh Ali Mohammed Hammamy

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic has affected the global socioeconomic and healthcare infrastructure. Vaccines have been the cornerstone in limiting the global spread of the pandemic. However, the mass scale vaccination has resulted in some unanticipated adverse events. Arguably the most serious of these has been the development of widespread thrombosis with viral-vectored vaccines. We present a case of extensive thrombosis associated with the messenger RNA (m-RNA) vaccine.

Citing Articles

Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series.

Bekal S, Husari G, Okura M, Huang C, Bukari M Cureus. 2023; 15(7):e41371.

PMID: 37546104 PMC: 10400017. DOI: 10.7759/cureus.41371.

Transient ischemic attack after mRNA-based COVID-19 vaccination during pregnancy: A case report.

Chang C, Kao S, Ding D World J Clin Cases. 2022; 10(27):9929-9935.

PMID: 36186193 PMC: 9516928. DOI: 10.12998/wjcc.v10.i27.9929.

References

Collins E, Carr M, Kim J, Lewis Jr J, Maleque N, Desai K . Immune thrombocytopenia in 2 healthy young women after the Pfizer-BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination. J Am Coll Emerg Physicians Open. 2021; 2(5):e12531. PMC: 8448486. DOI: 10.1002/emp2.12531. View

Finsterer J, Redzic Z . Symptomatic peduncular, cavernous bleeding following SARS-CoV-2 vaccination induced immune thrombocytopenia. Brain Hemorrhages. 2021; 2(4):169-171. PMC: 8443534. DOI: 10.1016/j.hest.2021.09.001. View

Pavenski K . Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine. TH Open. 2021; 5(3):e335-e337. PMC: 8459176. DOI: 10.1055/s-0041-1732342. View

Qasim H, Ali E, Yassin M . Immune thrombocytopenia relapse post covid-19 vaccine in young male patient. IDCases. 2021; 26:e01344. PMC: 8595970. DOI: 10.1016/j.idcr.2021.e01344. View

Kirpalani A, Garabon J, Amos K, Patel S, Sharma A, Lalgudi Ganesan S . Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab. Br J Haematol. 2021; 196(1):e11-e14. PMC: 8444813. DOI: 10.1111/bjh.17782. View

Montastruc J, Lafaurie M, de Canecaude C, Montastruc F, Bagheri H, Durrieu G . COVID-19 vaccines: A perspective from social pharmacology. Therapie. 2021; 76(4):311-315. PMC: 8161798. DOI: 10.1016/j.therap.2021.05.010. View

Innao V, Urso S, Insalaco M, Borraccino A, Consoli U . Immune Thrombotic Thrombocytopenic Purpura following Pfizer-BioNTech anti-COVID-19 vaccination in a patient healed from lymphoma after allogeneic hematopoietic stem cell transplantation. Thromb Res. 2022; 210:91-93. PMC: 8723754. DOI: 10.1016/j.thromres.2021.12.029. View

Vaira L, Podda L, Doneddu P, Careddu M, Fozza C, De Riu G . Secondary thrombocytopenia after SARS-CoV-2 vaccine: Report of a case of hemorrhage and hematoma after minor oral surgery. J Stomatol Oral Maxillofac Surg. 2021; 123(2):95-97. PMC: 8310415. DOI: 10.1016/j.jormas.2021.07.010. View

Shah P, Gelnick S, Jonisch J, Verma R . CENTRAL RETINAL VEIN OCCLUSION FOLLOWING BNT162B2 (PFIZER-BIONTECH) COVID-19 MESSENGER RNA VACCINE. Retin Cases Brief Rep. 2022; 17(4):441-444. DOI: 10.1097/ICB.0000000000001214. View

10.

Guney T, Can F, Akinci S, Kosemehmetoglu O, Dilek I . Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine. Turk J Haematol. 2021; 39(1):74-75. PMC: 8886268. DOI: 10.4274/tjh.galenos.2021.2021.0537. View

11.

Finsterer J, Nics S . Venous sinus thrombosis after the second jab of an mRNA-based SARS-CoV-2 vaccine. Brain Hemorrhages. 2021; 3(1):36-38. PMC: 8651552. DOI: 10.1016/j.hest.2021.12.001. View

12.

Yamaguchi Y, Kimihira L, Nagasawa H, Seo K, Wada M . Cerebral Venous Sinus Thrombosis After BNT162b2 mRNA COVID-19 Vaccination. Cureus. 2021; 13(10):e18775. PMC: 8590453. DOI: 10.7759/cureus.18775. View

13.

Shah S, Dolkar S, Mathew J, Vishnu P . COVID-19 vaccination associated severe immune thrombocytopenia. Exp Hematol Oncol. 2021; 10(1):42. PMC: 8280588. DOI: 10.1186/s40164-021-00235-0. View

14.

King E, Towner E . A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination. Am J Case Rep. 2021; 22:e931478. PMC: 8311388. DOI: 10.12659/AJCR.931478. View

15.

Rodriguez C, Perez-Nieva A, Maiz L, Meijon M, Llamas P, Monreal M . Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study. Thromb Res. 2021; 208:1-3. PMC: 8501513. DOI: 10.1016/j.thromres.2021.10.002. View

16.

Latkin C, Dayton L, Yi G, Konstantopoulos A, Boodram B . Trust in a COVID-19 vaccine in the U.S.: A social-ecological perspective. Soc Sci Med. 2021; 270:113684. PMC: 7834519. DOI: 10.1016/j.socscimed.2021.113684. View

17.

Chamarti K, Dar K, Reddy A, Gundlapalli A, Mourning D, Bajaj K . Thrombotic Thrombocytopenic Purpura Presentation in an Elderly Gentleman Following COVID Vaccine Circumstances. Cureus. 2021; 13(7):e16619. PMC: 8381440. DOI: 10.7759/cureus.16619. View

18.

Bruijn S, Maes M, De Waele L, Vanhoorelbeke K, Gadisseur A . First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination. J Thromb Haemost. 2021; 19(8):2014-2018. PMC: 8236927. DOI: 10.1111/jth.15418. View

19.

Shimazawa R, Ikeda M . Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech). J Pharm Policy Pract. 2021; 14(1):46. PMC: 8165345. DOI: 10.1186/s40545-021-00326-7. View

20.

Doroshenko A . The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions-Ending the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(6):e2111675. DOI: 10.1001/jamanetworkopen.2021.11675. View